Bristol Myers Squibb Company $BMY Shares Sold by M&T Bank Corp

Key Points

• Bristol Myers Squibb: M&T Bank Corp reduced its position by 93.2% in Q4, selling 711,415 shares and leaving 51,961 shares valued at $2.80M.
• EVP David V. Elkins sold 30,000 shares on April 1 at an average of $61.67 (~$1.85M), trimming his holding by 15.85% to 159,248 shares.
• The company missed quarterly EPS ($1.26 vs. $1.65 expected), set FY2026 guidance of 6.05–6.35 EPS, and announced a $0.63 quarterly dividend (≈4.4% yield).

M&T Bank Corp lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 93.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,961 shares of the biopharmaceutical company's stock after selling 711,415 shares during the period. M&T Bank Corp's holdings in Bristol Myers Squibb were worth $2,803,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of BMY. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the second quarter worth $25,000. Harbor Capital Advisors Inc. grew its stake in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 313 shares in the last quarter. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Bristol Myers Squibb during the third quarter worth $35,000. JPL Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the third quarter worth $36,000. Finally, Beacon Financial Strategies CORP acquired a new position in shares of Bristol Myers Squibb during the fourth quarter worth $38,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the company's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.05% of the company's stock.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $57.86 on Tuesday. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The company has a market capitalization of $118.13 billion, a PE ratio of 16.77, a P/E/G ratio of 0.17 and a beta of 0.27. The company has a fifty day moving average of $59.63 and a two-hundred day moving average of $54.31.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the prior year, the company earned $1.67 EPS. The business's revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.28 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio is presently 73.04%.

Analysts Set New Price Targets

A number of brokerages recently commented on BMY. Cantor Fitzgerald boosted their target price on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 8th. Barclays assumed coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an "overweight" rating and a $75.00 price objective for the company. Scotiabank restated a "sector perform" rating and issued a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Leerink Partners upped their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an "outperform" rating in a research note on Tuesday, January 13th. Finally, Piper Sandler restated an "overweight" rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.